60c210ff-d245-40d2-9de9-7b799cc3ffc9
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.400
- KRAS_SIGNALING_DN+0.400
- APICAL_JUNCTION+0.300
- COAGULATION+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- ESTROGEN_RESPONSE_EARLY+0.300
- ESTROGEN_RESPONSE_LATE+0.300
- MYOGENESIS+0.300
- PANCREAS_BETA_CELLS+0.300
- ANGIOGENESIS+0.200
Top 10 suppressed
- E2F_TARGETS-0.700
- G2M_CHECKPOINT-0.700
- MITOTIC_SPINDLE-0.500
- MTORC1_SIGNALING-0.500
- MYC_TARGETS_V1-0.500
- MYC_TARGETS_V2-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.500
- PI3K_AKT_MTOR_SIGNALING-0.400
- PROTEIN_SECRETION-0.400
- ANDROGEN_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d93b1580-c20d-4611-ac99-c0cb33f37a45 | — | — | 0.900 |
| 2 | SJEPD028_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.899 |
| 3 | TCGA-KQ-A41P-01A-12R-A33J-07 | — | — | 0.873 |
| 4 | BS_CVGFNCBJ | low-grade glioma | — | 0.861 |
| 5 | BS_7XRN3CFX | low-grade glioma | — | 0.861 |
| 6 | SJEPD001515_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.859 |
| 7 | TCGA-E9-A3X8-01A-31R-A22U-07 | — | B | 0.858 |
| 8 | BS_AKRHBPNZ | Ganglioglioma | — | 0.846 |
| 9 | TCGA-MP-A4TD-01A-32R-A262-07 | — | cohortA3 | 0.845 |
| 10 | R62 | — | — | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.400 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.400 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |